Partners

Our Partnerships

TCOLF engages with public and private Research Institutes, High Education Institutions and Companies that work in the research areas supported and that share its principles. The Foundation supports collaborative projects between one of these organizations (the “Home Institution”), and GSK DDW (the “Host Institution”).

Portfolio of complete and ongoing projects Open Lab scientists work at the Tres Cantos campus during part or the whole project duration, accessing GSK drug discovery expertise as part of an integrated team to develop new medicines for diseases of the developing world.
Home Institutions supported to date include:

Autonomous University of Madrid
Calibr (The California Institute for Biomedical Research)
CICbioGUNE (Center for Cooperative Research in Biosciences)
CIDR (Center for Infectious Disease Research)
CRESIB (Barcelona Centre for International Health Research)
CSIC (Spanish National Research Council)
CSRC (Caucaseco Scientific Research Center)
Durham University
Edinburgh University
ETH Zürich (Swiss Federal Institute of Technology)
Harvard Medical School
Harvard School for Public Health
INSERM / INTS (Institut National de la Transfusion Sanguine)
Institut Pasteur Korea
LSHTM (London School of Hygiene and Tropical Medicine)
Mahidol University
Martin Luther University Halle-Wittenberg
MBL (Marine Biological Laboratory)
McGill University
Monash University
MRC (Medical Research Council)
New York University
Northeastern University
Omnia Molecular
Sapienza University of Rome
Structural Genomics Consortium / University of Oxford
SUNY Upstate Medical University
TeagueMedChem
University of Birmingham
University of British Columbia
University of Dundee
University of Florida
University of Georgia
University of Glasgow
University of Helsinki
University of León
University of Liverpool
University of Minnesota
University of Sydney
University San Pablo CEU
Weill Cornell Medical College

GSK

GSK is committed to researching new treatments for diseases that affect millions of people in the world’s developing nations. To facilitate the establishment of the Tres Cantos Open Lab Foundation, GSK provided £5 million of an initial investment to support the Foundation’s objectives. In October 2012, two years after the Tres Cantos Open Lab Foundation was first established, GSK announced that it would double its funding by making an additional £5m available thus reinforcing its commitment to the value of openness and collaboration.